DNMT1 and Myelodysplasia: Despite promising preclinical studies showing atheroprotective effects of DNMT inhibitors (e.g., 5-azacytidine and 5-aza-2-deoxycytidine) [96], which are approved for myelodysplasia treatment, clinical trials for atherosclerotic CVD remain absent due to the systemic off-target effects of DNMT inhibition [97,98].